|
gptkbp:instanceOf
|
gptkb:biotechnology
gptkb:public_company
|
|
gptkbp:alsoKnownAs
|
gptkb:Moderna
|
|
gptkbp:awarded
|
gptkb:TIME_100_Most_Influential_Companies_(2021)
|
|
gptkbp:CEO
|
gptkb:Stéphane_Bancel
|
|
gptkbp:collaboratesWith
|
gptkb:National_Institutes_of_Health
gptkb:U.S._government
gptkb:Vertex_Pharmaceuticals
gptkb:Carisma_Therapeutics
gptkb:AstraZeneca
gptkb:Merck_&_Co.
|
|
gptkbp:COVID-19VaccineApproval
|
December 2020 (US EUA)
January 2021 (EU)
|
|
gptkbp:focus
|
vaccines
mRNA therapeutics
|
|
gptkbp:founded
|
2010
|
|
gptkbp:founder
|
gptkb:Robert_S._Langer
gptkb:Derrick_Rossi
gptkb:Kenneth_R._Chien
gptkb:Noubar_Afeyan
gptkb:Stéphane_Bancel
gptkb:Timothy_A._Springer
|
|
gptkbp:headquartersLocation
|
gptkb:Cambridge,_Massachusetts,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ModernaTX, Inc.
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:IPODate
|
December 7, 2018
|
|
gptkbp:keyPerson
|
gptkb:Melissa_J._Moore
gptkb:Noubar_Afeyan
gptkb:Paul_Burton
gptkb:Stéphane_Bancel
gptkb:Stephen_Hoge
|
|
gptkbp:marketCap
|
varies (over $50 billion at peak in 2021)
|
|
gptkbp:netIncome
|
-$4.7 billion (2023)
|
|
gptkbp:notableProduct
|
gptkb:Spikevax
gptkb:mRNA-1273
vaccine
|
|
gptkbp:numberOfEmployees
|
~4,500 (2023)
|
|
gptkbp:parentCompany
|
independent
|
|
gptkbp:patent
|
gptkb:mRNA_vaccine_technology
|
|
gptkbp:researchInterest
|
infectious diseases
oncology
cardiovascular diseases
rare diseases
autoimmune diseases
|
|
gptkbp:revenue
|
$6.8 billion (2023)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:stockSymbol
|
gptkb:MRNA
|
|
gptkbp:subsidiary
|
gptkb:Moderna_UK
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|
|
gptkbp:website
|
https://www.modernatx.com/
|
|
gptkbp:bfsParent
|
gptkb:Moderna,_Inc.
|
|
gptkbp:bfsLayer
|
6
|